Methylparaben concentration in commercial Brazilian local anesthetics solutions

FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOTo detect the presence and concentration of methylparaben in cartridges of commercial Brazilian local anesthetics. Twelve commercial brands (4 in glass and 8 in plastic cartridges) of local anesthetic solutions for use in dentistry were purchased from the Brazilian market and analyzed. Different lots of the commercial brands were obtained in different Brazilian cities (Piracicaba, Campinas and Sao Paulo). Separation was performed using high performance liquid chromatography (HPLC) with UV-Vis detector. The mobile phase used was acetonitrile: water (75:25 - v/v), pH 4.5, adjusted with acetic acid at a flow rate of 1.0 ml.min(-1). When detected in the solutions, the methylparaben concentration ranged from 0.01% (m/v) to 0.16% (m/v). One glass and all plastic cartridges presented methylparaben. 1. Methylparaben concentration varied among solutions from different manufacturers, and it was not indicated in the drug package inserts; 2. Since the presence of methylparaben in dental anesthetics is not regulated by the Brazilian National Health Surveillance Agency (ANVISA) and this substance could cause allergic reactions, it is important to alert dentists about its possible presence204444448FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOsem informaçã

Pharmacokinetic and local toxicity studies of liposome-encapsulated and plain mepivacaine solutions in rats

FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOThe pharmacokinetics and the local toxicity of commercial and liposome-encapsulated mepivacaine formulations injected intra-orally in rats were studied. Animals were divided in groups (n=4-6) and treated with 0.1 mL of the formulations: 2% mepivacaine with 1:100,000 epinephrine (MVC(2%EPI)), 3% mepivacaine (MVC(3%)), and 2% liposome-encapsulated mepivacaine (MVC(LUV)). The results showed that the 2% liposome-encapsulated mepivacaine reduced C(max), prolonged AUC(0-infinity) and t(1/2) compared with 3% plain and 2% vasoconstritor-associated mepivacaine, after intraoral injection. In addition, it was also observed that liposomal mepivacaine might protect the tissue against local inflammation evoked by plain or vasoconstrictors-associated mepivacaine, giving supporting evidence for its safety and possible clinical use in dentistry1726876FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOFAPESP [Proc 06/00121-9]2006/00121-9sem informaçã

Effects Of The Epinephrine-felypressin Association To Bupivacaine Upon The Arterial Pressure, In Dogs [avaliacao Dos Efeitos Da Associacao De Adrenalina E Felipressina A Bupivacaina Sobre A Pressao Arterial De Caes]

[No abstract available]105171

Blood glucose determination in normal and alloxan-diabetic rats after administration of local anesthetics containing vasoconstrictors

Normal and alloxan-diabetic rats were injected submucously in the posterior region of the upper jaw with bupivacaine (1.28 mg/kg) containing adrenaline (0.0012 mg/kg), or lignocaine (5.14 mg/kg) containing noradrenaline (0.005 mg/kg). Blood glucose was determined at zero (before administration), 0.5, 1, 2, 3 and 4 hours after the administration of the anesthetics. Statistical analysis (ANOVA and Tukey's test, P < 0.05) showed significant differences between treatments at 1 hour in normal rats. Bupivacaine with adrenaline induced a significantly greater blood glucose level than lignocaine with noradrenaline. The effect was significant but of short duration. In alloxan-diabetic rats, anesthetics containing adrenaline or noradrenaline did not induce increased blood glucose levels.Normal and alloxan-diabetic rats were injected submucously in the posterior region of the upper jaw with bupivacaine (1.28 mg/kg) containing adrenaline (0.0012 mg/kg), or lignocaine (5.14 mg/kg) containing noradrenaline (0.005 mg/kg). Blood glucose was determined at zero (before administration), 0.5, 1, 2, 3 and 4 hours after the administration of the anesthetics. Statistical analysis (ANOVA and Tukey's test, P < 0.05) showed significant differences between treatments at 1 hour in normal rats. Bupivacaine with adrenaline induced a significantly greater blood glucose level than lignocaine with noradrenaline. The effect was significant but of short duration. In alloxan-diabetic rats, anesthetics containing adrenaline or noradrenaline did not induce increased blood glucose levels91333

Articaine and lignocaine efficiency in infiltration anaesthesia: a pilot study

FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOThe purpose of this study was to evaluate the onset of action of pulpal and soft tissue anaesthesia, and pain experience after buccal and palatal infiltrative injections with 4% articaine with 1: 100,000 adrenaline, and 2% lignocaine with 1: 100,000 adrenaline. A double blind cross-over study was conducted with 20 healthy adult subjects who, in two appointments at least two weeks apart, randomly received an infiltration anaesthesia with the solutions in the buccal and palatal regions of the upper right canine. The tooth was tested with a pulp tester before ( to establish its baseline response), and after the injection, until return to the base threshold level. The pain experience caused by palatal injection was verified by the visual analogue scale ( VAS). Data were analysed using Wilcoxons test ( alpha = 0.05). There were no significant statistical differences between the solutions with respect to VAS ( p = 0.45), onset of action ( p = 0.80) and pulpal ( p = 0.08) and soft tissue ( p = 0.18) anaesthesia duration, although pulpal anaesthesia may have reached statistical significance if a higher number of volunteers had been used. Under the conditions of this study it can be concluded that both anaesthetic solutions showed similar pain experience19714546FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO1999/12005-8; 1999/11993-

A double-blind comparison of 0.5% bupivacaine with 1 : 200,000 epinephrine and 0.5% levobupivacaine with 1 : 200,000 epinephrine for the inferior alveolar nerve block

This double-blind cross-over study compared the anesthetic success and onset and duration of lip and pulpal anesthesia of 0.5% bupivacaine and levobupivacaine solutions, both with 1:200,000 epinephrine, when administered for inferior alveolar nerve anesthesia. Thirty healthy volunteers were randomly anesthetized using one of the solutions. The inferior canine, second premolar, and molar were tested with electric stimulation. The pulpal anesthetic success rates for bupivacaine and levobupivacaine were 80% and 76.66%, respectively, for molars, 76.66% (both solutions) for premolars, and 70% (both solutions) for canines. At least 250 minutes of pulpal anesthesia was achieved. There were no significant differences between the solutions considering the measured parameters (P > .05). Because of the similar anesthetic behavior of the 2 solutions in this study and the low toxicity related in the literature for levobupivacaine, there is justification for replacing bupivacaine with levobupivacaine for inferior alveolar nerve local anesthesia101444244

Allergic reaction after rubber dam placement

In the last few years allergic reactions to natural rubber latex (NRL) have increased in dental practice affecting both the dental team and patients. Some case reports discuss the potential risks of hypersensitivity to NRL products. An adverse patient reaction after dental rubber dam placement is reported. About 1 min after the isolation of the tooth with a rubber dam the patient presented signs and symptoms of hypersensitivity. Oxygen and intravenous hydrocortisone were administered and the patient kept under observation, After 2 h she had stable vital signs and no more allergies symptoms. It is unclear whether components of the NRL dam or the cornstarch powder incorporated with the rubber dam was responsible for the allergic reaction. Dentists must be aware of the health problem and be prepared for an adequate management in dental practice.26318218

Liposomal encapsulation improves the duration of soft tissue anesthesia but does not induce pulpal anesthesia

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Study Objective: To compare the topical and the pulpal anesthesia efficacy of liposomal and plain benzocaine formulations Design: Double-blinded, randomized crossover study. Setting: University ambulatory dental center Patients: 30 ASA physical status 1 volunteers Interventions: Volunteers received, in three different sessions, topical application of liposome-encapsulated 10% benzocaine (LB10), 10% benzocaine gel (B10), and 20% benzocaine gel (B20) in the right maxillary canine mucobuccal fold Measurements: Pain associated with the needle insertion was rated by visual analog scale (VAS) and the duration of topical anesthesia was recorded Pulpal anesthesia was evaluated using an electric pulp tester Main Results: VAS values (median. 1st - 3rd quartiles) were 17 cm (11 - 25), 14 cm (3 - 22), and 21 cm (9 21) for B10, LB10, and 1320, respectively No differences were noted among the groups (Friedman test, P = 0 58) Soft tissue anesthesia was also not different The LB10 [10 (8 - 12) min] showed longer soft tissue anesthesia (Friedman test, P < 0 01) than the other agents [1310 = 8 (5 - 10) min, and B20 = 7 (6 - 9) min] None of the topical benzocaine formulations tested induced pulpal anesthesia Conclusions: The encapsulation of benzocaine into liposome increased the duration of soft tissue anesthesia However, it did not induce pulpal anesthesia (C) 2010 Elsevier Inc All rights reserved225313317DFL Ind Corn Ltda, Rio de Janeiro, BrazilConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq